Home > Insider Trading > Filing (0001209191-21-014053)

Filing Details

Accession Number:: 0001209191-21-014053
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-24 20:30:46
Reporting Period:: 2021-02-22

Accepted Time:: 2021-02-24 20:30:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	55 Cambridge Parkway, Suite 800E Cambridge MA 02142		Yes	No	No	No

Transaction Summary

Sold:	4,784,404 shares	Avg. Price: $152.59	Total Value: $730,069,590.44
Number of Shares After Transactions:	14,623,159 shares

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-22	161,887	$159.18	19,245,278	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	54,409	$160.37	19,190,869	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	30,808	$160.96	19,160,061	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	250,501	$162.36	18,909,560	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	366,471	$163.25	18,543,089	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	189,200	$164.13	18,353,889	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	165,578	$165.47	18,188,311	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	351,578	$166.30	17,837,101	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	122,715	$167.10	17,714,386	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	58,377	$168.11	17,656,009	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	54,274	$169.14	17,601,735	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-22	30,968	$170.03	17,570,797	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	9,985	$136.48	17,560,812	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	122,142	$137.29	17,438,670	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	46,222	$138.56	17,392,448	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	56,435	$139.64	17,336,013	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	102,852	$140.24	17,233,161	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	70,631	$141.46	17,162,530	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	117,011	$142.76	17,045,519	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	397,126	$143.57	16,648,393	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	405,551	$144.55	16,242,842	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	357,316	$145.48	15,885,526	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	307,795	$146.64	15,577,731	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	292,483	$147.57	15,285,248	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	268,688	$148.52	15,016,560	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	179,268	$149.63	14,837,292	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	190,710	$150.51	14,646,582	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
Common Stock	Disposition	2021-02-23	23,423	$151.29	14,623,159	No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.
No	4	S	Indirect	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,464,359	Indirect	By Flagship VentureLabs IV LLC and Flagship Pioneering, Inc.
Common Stock	2,101,703	Direct

Footnotes

These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020.
Represents 135,986 shares sold by Flagship Fund IV and 25,901 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.65 to $159.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Represents 45,703 shares sold by Flagship Fund IV and 8,706 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.65 to $160.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 25,879 shares sold by Flagship Fund IV and 4,929 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.65 to $161.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 210,421 shares sold by Flagship Fund IV and 40,080 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.79 to $162.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 307,835 shares sold by Flagship Fund IV and 58,636 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.79 to $163.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 158,928 shares sold by Flagship Fund IV and 30,272 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.79 to $164.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 139,086 shares sold by Flagship Fund IV and 26,492 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.79 to $165.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 295,016 shares sold by Flagship Fund IV and 56,194 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.79 to $166.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 103,081 shares sold by Flagship Fund IV and 19,634 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.79 to $167.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 49,037 shares sold by Flagship Fund IV and 9,340 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.79 to $168.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 45,589 shares sold by Flagship Fund IV and 8,685 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.80 to $169.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 25,989 shares sold by Flagship Fund IV and 4,949 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.85 to $170.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 8,387 shares sold by Flagship Fund IV and 1,598 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.01 to $137.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 102,600 shares sold by Flagship Fund IV and 19,542 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.01 to $137.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 38,826 shares sold by Flagship Fund IV and 7,396 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.03 to $139.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 47,406 shares sold by Flagship Fund IV and 9,029 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.05 to $140.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 86,395 shares sold by Flagship Fund IV and 16,457 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.05 to $140.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 59,330 shares sold by Flagship Fund IV and 11,301 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.06 to $142.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 98,290 shares sold by Flagship Fund IV and 18,721 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.06 to $143.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 333,586 shares sold by Flagship Fund IV and 63,540 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.06 to $144.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 340,662 shares sold by Flagship Fund IV and 64,889 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.06 to $145.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 300,146 shares sold by Flagship Fund IV and 57,170 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.06 to $146.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 258,547 shares sold by Flagship Fund IV and 49,248 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.07 to $147.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 245,686 shares sold by Flagship Fund IV and 46,797 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.07 to $148.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 225,698 shares sold by Flagship Fund IV and 42,990 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.07 to $149.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 150,585 shares sold by Flagship Fund IV and 28,683 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.07 to $150.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 160,196 shares sold by Flagship Fund IV and 30,514 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.08 to $151.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Represents 19,676 shares sold by Flagship Fund IV and 3,747 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.08 to $151.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Following the transactions reported herein, 10,417,023 shares are held directly by Flagship Fund IV and 4,206,136 shares are held directly by Flagship Fund IV-Rx.
11,460,435 shares are held directly by Flagship VentureLabs IV LLC ("VentureLabs IV") and 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.